meloxicam | meloxicam tablets 15 mg 20 pcs.

Latin name

Meloxicam

Release form

Tablets.



packaging 20 pcs

Pharmacological action

Meloxicam has an anti-inflammatory, analgesic, antipyretic effect.

Indications

Inflammatory and degenerative joint diseases accompanied by pain: arthritis, incl. rheumatoid arthritis, acute osteoarthritis, chronic polyarthritis, ankylosing spondylitis (ankylosing spondylitis), pain with osteoarthritis and radiculitis.

Contraindications

Hypersensitivity (including other NSAIDs), the “aspirin” triad (a combination of bronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance of the acetylsalicylic acid and intestinal ulcer and pyrazolone diseases) gastrointestinal, cerebrovascular or other bleeding / hemorrhage severe heart failure, severe liver failure, severe renal failure (if hemodialysis is not performed), age up to 15 years.

Use during pregnancy and lactation

The drug is not recommended for use during pregnancy and lactation.

Composition

1 tablet contains:

Active ingredient: meloxicam - 7.5 or 15 mg

Excipients:

lactose (milk sugar),

microcrystalline cellulose,

sodium citrate dihydrate,

povidone (polyvinylpyrrolidone),

carboxymethyl starch sodium calcium starch (sodium carboxymethyl starch acid) stearate.

Dosage and administration of

meloxicam is taken orally. The dose is selected individually, it is necessary to use the lowest effective dose for a minimum period of time. Inside, with food, without chewing, at a dose of 7.5-15 mg once a day. The maximum daily dose is 15 mg, in patients with severe renal failure on hemodialysis - 7.5 mg. With a slight or moderate decrease in renal function (creatinine clearance> 25 ml / min), as well as with cirrhosis in a stable clinical state, dose adjustment is not required. The initial dose in patients with an increased risk of side effects is 7.5 mg / day.

Side effects of the

From the digestive tract:> 1% - dyspepsia, nausea, vomiting, abdominal pain, constipation / diarrhea, flatulence 0.1–1% - stomatitis, transient changes in liver function indices (increased levels of transaminases or bilirubin) , belching, esophagitis, gastric and duodenal ulcer, latent or macroscopically visible gastrointestinal bleeding

From the nervous system and sensory organs:> 1% - headache, dizziness 0.1–1% - vertigo, drowsiness, tinnitus

From the cardiovascular system and the shelter (Blood, hemostasis):> 1% - swelling, anemia 0.1-1% - increase in blood pressure, heart rate, flushing, hemogram changes, including a change in the number of individual types of white blood cells, leukopenia, thrombocytopenia.

From the respiratory system: exacerbation of bronchial asthma, cough.

From the genitourinary system: 0.1–1% - change in indicators of kidney function (increased levels of creatinine and / or blood urea)

From the skin:> 1% - skin rash, itching 0.1–1% - urticaria.

ЛРкарствРнноРвзаимодРйствимbr>
При одноврРмРнном примРнРнии с ацРтилсалициловой кислотой и другими НПВС увРличиваРтся риск возникновРния эрозивно-язвРнн х поражРний и кровотРчРний из ЖКТ. При одноврРмРнном примРнРнии с гипотРнзивн ми срРдствами возможно снижРниРэффРктивности дРйствия послРдних.

При одноврРмРнном примРнРнии с прРпаратами лития возможна кумуляция лития и увРличРниРРго токсичРского дРйствия (рРкомРндуРтся контроль концРнтрации лития в крови). ОдноврРмРнноРпримРнРниРс мРтотрРксатом способствуРт усилРнию побочного дРйствия послРднРго на кровРтворную систРму (сущРствуРт опасность развития анРмии и лРйкопРнии.

НРобходим пРриодичРский контроль общРго анализа крови). СовмРстноРпримРнРниРс диурРтиками и циклоспорином приводит к возрастанию риска развития почРчной нРдостаточности. При одноврРмРнном использовании с внутриматочн ми контрацРптивн ми срРдствами возможно снижРниРэффРктивности дРйствия послРдних.

При одноврРмРнном примРнРнии с антикоагулянтами (гРпарин, тиклопидин, варфарин), а такжРс тромболитичРскими прРпаратами (стрРптокиназа, фибринолизин) увРличиваРтся риск развития кровотРчРний (слРдуРт пРриодичРски контролировать показатРли свРрт ваРмости крови).

ОдноврРмРнноРиспользованиРс колРстирамином усиливаРт в вРдРниРмРлоксикама чРрРз ЖКТ (в рРзультатРсвяз вания мРлоксикама). При одноврРмРнном приРмРмРлоксикама с антацидами фармакокинРтичРского взаимодРйствия нРобнаружРно.

Overdose

Symptoms:

Increased side effects.

Treatment:

Gastric lavage, activated charcoal intake (within the next hour), symptomatic therapy.

Cholestyramine accelerates the elimination of the drug from the body. Forced diuresis, urinary alkalinity, hemodialysis are ineffective due to the high association of meloxicam with blood proteins. No specific antidotes and antagonists were detected.

Storage conditions

The drug should be stored in a dry, dark place at a temperature of no higher than 25 РC.

Expiration

3 years.

Deystvuyuschee substances

meloxicam

Pharmacy terms

prescription p17pffpf39 pf47 dffpffpf39pffpf39pffpf39pffpf39

pharmacy delivery terms Prescription

dosage form

dosage form PMA



Vertex Russia,